The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study.
Muhammet Ali Kaplan
No relevant relationships to disclose
Abdurrahman Isikdogan
No relevant relationships to disclose
Dogan Koca
No relevant relationships to disclose
Mehmet Kucukoner
No relevant relationships to disclose
Ozge Gumusay
No relevant relationships to disclose
Ramazan Yildiz
No relevant relationships to disclose
Ilhan Oztop
No relevant relationships to disclose
Lutfiye Demir
No relevant relationships to disclose
Caglayan Geredeli
No relevant relationships to disclose
Murat Kocer
No relevant relationships to disclose
Ülkü Yalçintas Arslan
No relevant relationships to disclose
Ali Inal
No relevant relationships to disclose
Ugur Coskun
No relevant relationships to disclose
Nur Sener
No relevant relationships to disclose
Mevlude Inanc
No relevant relationships to disclose
Emin Tamer Elkiran
No relevant relationships to disclose
Nuriye Ozdemir
No relevant relationships to disclose
Ayse Gok Durnali
No relevant relationships to disclose
Ali Suner
No relevant relationships to disclose
Suleyman Alici
No relevant relationships to disclose